- Home
- EZPW vs PLRX Comparison
EZPW vs PLRX Comparison
Compare EZPW & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EZPW
- PLRX
- Stock Information
- Founded
- EZPW 1989
- PLRX 2015
- Country
- EZPW United States
- PLRX United States
- Employees
- EZPW N/A
- PLRX N/A
- Industry
- EZPW Other Specialty Stores
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- EZPW Consumer Discretionary
- PLRX Health Care
- Exchange
- EZPW Nasdaq
- PLRX Nasdaq
- Market Cap
- EZPW 736.7M
- PLRX 165.5M
- IPO Year
- EZPW 1991
- PLRX 2020
- Fundamental
- Price
- EZPW $13.29
- PLRX $1.51
- Analyst Decision
- EZPW Buy
- PLRX Hold
- Analyst Count
- EZPW 2
- PLRX 10
- Target Price
- EZPW $17.75
- PLRX $9.79
- AVG Volume (30 Days)
- EZPW 539.2K
- PLRX 4.5M
- Earning Date
- EZPW 04-30-2025
- PLRX 03-03-2025
- Dividend Yield
- EZPW N/A
- PLRX N/A
- EPS Growth
- EZPW 77.06
- PLRX N/A
- EPS
- EZPW 1.14
- PLRX N/A
- Revenue
- EZPW $1,181,781,000.00
- PLRX N/A
- Revenue This Year
- EZPW $9.42
- PLRX N/A
- Revenue Next Year
- EZPW $7.08
- PLRX $46.66
- P/E Ratio
- EZPW $11.83
- PLRX N/A
- Revenue Growth
- EZPW 8.95
- PLRX N/A
- 52 Week Low
- EZPW $9.65
- PLRX $1.26
- 52 Week High
- EZPW $14.50
- PLRX $16.52
- Technical
- Relative Strength Index (RSI)
- EZPW 52.93
- PLRX 25.04
- Support Level
- EZPW $13.09
- PLRX $1.38
- Resistance Level
- EZPW $13.55
- PLRX $1.68
- Average True Range (ATR)
- EZPW 0.32
- PLRX 0.33
- MACD
- EZPW -0.07
- PLRX 0.24
- Stochastic Oscillator
- EZPW 42.11
- PLRX 15.68
About EZPW EZCORP Inc. Non Voting
EZCORP Inc is a United States-based company engaged in offering pawn loans in the United States and Mexico. It also offers short-term unsecured loans and other consumer financial products, and buy and sell second-hand goods. The operating segments of the company are us Pawn, Latin America Pawn, and other international. us Pawn segment includes all pawn activities in the United States. Latin America Pawn segment includes all pawn activities in Mexico and other parts of Latin America. The company generates revenue from merchandise sales, jewelry scrapping sales, and pawn service charges, of which key revenue is derived from the merchandise sales which are primarily collateral forfeited from pawn lending operations and used merchandise purchased from the customers.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.